肝细胞癌根治术后辅助性经导管动脉化疗栓塞术治疗的研究进展

Research progress of adjuvant therapy based on transcatheter arterial chemoembolization after radical resectionofhepatocellularcarcinoma

肝细胞癌是全世界最常见的消化道恶性肿瘤之一,其恶性程度高、侵袭性极强、术后复发率高、术后总生存率低。经导管动脉化疗栓塞术(TACE)是目前公认的最常用的肝癌局部治疗方法之一,对于具有高复发风险(如肿瘤的最大径>5cm、术前甲胎蛋白高水平、大血管侵犯、伴微血管侵犯等)的肝癌根治性切除术后患者,术后辅助性经导管动脉化疗栓塞术(PA-TACE)可以为其预后带来获益。同时,PA-TACE联合其他如抗病毒、分子靶向、免疫、消融放射以及中药治疗等已经显示出较好的疗效。本文就肝细胞癌根治术后以PA-TACE为主的研究进展进行综述.

Hepatocellular carcinoma(HCC)is one of the most common malignant tumors of the digestive tract in the world,with high malignancy,strong invasion,high postoperative recurrence rate and low overall survival rate.Transcatheter arterial chemoembolization(TACE)has been recognized as one of the most commonly used local treatment methods for liver cancer.For high risk of recurrence(such as the diameter of the tumor larger(>5 cm in diameter),preoperative AFP levels,and large vascular invasion,with microvascular invasion,etc.)after radical resection of liver cancer patients,Postoperative adjuvant transarterial chemoembolization(PA-TACE)can bring benefits to the prognosis of patients with liver cancer.At the same time,TACE combined with other therapies such as antiviral therapy,molecular targeted therapy,immunotherapy,ablative radiation therapy and traditional Chinese medicine therapy have shown good efficacy.This article reviews the research progress of adjuvant therapy based on PA-TACE after radical resection of hepatocellular carcinoma.